Skip to main content
Toggle navigation
Login
Search
Home
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Favorite
Like
Post
Print
Li-Juan Jiang, Ph. D. (she/her/hers)
Vice President
Enanta Pharmaceuticals, Inc.
Poster(s):
(573) Oral STAT6 Inhibitor EPS-3903 Demonstrates Good Preclinical In Vivo Tolerability without Reactive Metabolites or Metabolic/Safety Liabilities
Thursday, April 16, 2026
11:30 AM - 12:30 PM
US ET
(723) Potent STAT6 Inhibitor EPS-3903 Has Excellent Preclinical Pharmacokinetics Enabling Sustained STAT6 Inhibition with Once-Daily Oral Dosing in Humans
Saturday, April 18, 2026
11:30 AM - 12:30 PM
US ET
